Related Experiment Videos
Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower
1Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA.
Insights
Patients with type 2 diabetes and coronary heart disease (CHD) benefit from aggressive lipid-lowering therapy. Specific statins like pravastatin and simvastatin, and gemfibrozil, reduce cardiovascular events in these high-risk individuals.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes significantly elevates coronary heart disease (CHD) risk, often exacerbated by abnormal lipid profiles.
- Insulin resistance, hyperinsulinaemia, hypertension, and elevated fibrinogen/plasminogen activator inhibitor contribute to cardiovascular risk, not fully managed by glycemic control.
- Aggressive lipid-lowering therapy has demonstrated substantial reductions in CHD risk among diabetic patients in major trials.
Purpose of the Study:
- To evaluate the efficacy of lipid-lowering therapies in reducing cardiovascular events in patients with type 2 diabetes and CHD.
- To compare the effectiveness and safety profiles of different lipid-lowering agents, including gemfibrozil, pravastatin, and simvastatin.
Main Methods:
- Review of large interventional trials assessing lipid-lowering therapy in diabetic patients with CHD.
- Analysis of data on fatal and non-fatal CHD events associated with specific lipid-lowering drugs.
Main Results:
- Gemfibrozil effectively reduced CHD events in diabetic patients with CHD, low HDL, and normal LDL.
- Pravastatin and simvastatin are the only HMG-CoA reductase inhibitors proven to decrease fatal and non-fatal CHD events in diabetic patients with CHD.
- Pravastatin exhibits a lower potential for drug-drug interactions, suggesting enhanced safety, especially in combination therapy for mixed dyslipidemias.
Conclusions:
- Aggressive lipid-lowering is crucial for managing cardiovascular risk in type 2 diabetes patients with CHD.
- Pravastatin and simvastatin offer proven benefits for CHD event reduction in this population.
- Pravastatin's safety profile may favor its use in combination therapies for comprehensive cardiovascular risk management.
Abstract:
Patients with type 2 diabetes are at high risk for coronary heart disease (CHD); frequently, these patients have abnormal lipid profiles, placing them at even greater risk. A syndrome of insulin resistance, hyperinsulinaemia, hypertension, and high levels of fibrinogen and plasminogen activator inhibitor contributes to cardiovascular risk, which is not sufficiently decreased by glycaemic control alone. In several large interventional trials, CHD risk in patients with diabetes was substantially reduced by aggressive lipid-lowering therapy. In patients with diabetes, CHD, low high-density lipoprotein levels, and normal low-density lipoprotein levels, gemfibrozil reduced fatal and non-fatal CHD events. For lipid-lowering in patients with diabetes and CHD, pravastatin and simvastatin are the only HMG-CoA reductase inhibitors shown to reduce fatal and non-fatal CHD events. Of these, pravastatin has less potential for drug-drug interactions and may be safer to use, particularly for combination therapy with fibric acid derivatives, as may now be important for CHD prevention in mixed dyslipidaemias.